NR3C2 and cancer: NY-ESO-1-antiMR antibody bound to the MR on DCs and NY-ESO-1-anti-DEC-205 on DCs, leading to stimulation of CD4+ and CD8+ T cells from peripheral blood mononuclear cells of cancer patients [61].